Pfizer

This study tests a new pneumococcal vaccine in adults 18 and older to see if it is safe and triggers a strong immune response. The vaccine is designed to protect against pneumococcal disease, which can cause pneumonia and other serious infections. Participants receive one shot an…

This large Phase 3 study tests a single shot of an experimental RSV vaccine in about 39,000 adults aged 60 and older. The goal is to see if the vaccine can prevent lower respiratory tract infections caused by RSV, a common virus that can be dangerous for older people. Participant…

This study looks at health records of over 800,000 adults to see how well the PCV20 vaccine prevents pneumonia and other lung infections. It focuses on people aged 18 and older who have a higher risk of getting pneumococcal disease. The goal is to compare pneumonia rates between …

This study tests a new pneumococcal vaccine (PG4) in healthy infants to see if it is safe and helps their bodies fight off germs that cause pneumonia and other infections. About 605 babies will receive either the new vaccine or a current one, with blood samples taken to measure p…

This study tests new versions of a vaccine to prevent severe diarrhea caused by the C. diff germ. Healthy adults aged 50 and older who have never had a C. diff infection can join. The goal is to see if the new vaccine formulations produce a strong immune response and are safe.

This large Phase 3 study tests a new vaccine (VLA15) to prevent Lyme disease, a tick-borne illness. About 12,500 healthy people aged 5 and older in high-risk areas of North America and Europe will receive either the vaccine or a placebo. The goal is to see if the vaccine safely r…

This study looks at how well the RSV vaccine (ABRYSVO) given during pregnancy prevents serious RSV lung infections in babies. Researchers will review health records of infants up to 12 months old who were hospitalized with breathing problems. They will compare RSV test results to…

This study checks how well the Prevnar 20 (PCV20) vaccine works in real life for people 65 and older. Researchers will look at medical records from over 22 million Medicare patients to see if the vaccine lowers the risk of serious lung infections like pneumonia. No new treatments…

This early-stage study is testing a new vaccine that protects against 20 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. Around 200 healthy Chinese adults, children, and infants will receive the vaccine according to age-specific schedules. …

This study examines how effective Pfizer's ABRYSVO vaccine is at preventing severe RSV infections in adults aged 60 and older. Researchers will analyze existing health records from routine doctor visits over several years, without actively enrolling participants. The goal is to u…

This study checks how well the ABRYSVO vaccine works when given to pregnant people to protect their babies from RSV, a serious lung infection. Researchers will compare health records of nearly 40,000 infants born to vaccinated versus unvaccinated mothers. The goal is to see if th…

This study looks at how well the ABRYSVO vaccine works when given to pregnant people to protect their babies from RSV, a leading cause of serious lung infections in infants. Researchers will analyze medical records of infants up to 6 months old in Western Pennsylvania over severa…

This early-stage study is testing a new experimental vaccine (PG4) to see if it is safe and tolerable in adults. About 380 healthy volunteers will receive either the new vaccine, a similar vaccine, a standard pneumococcal vaccine, or a placebo. Participants will be followed for u…

This study looks at how safe the PREVENAR 20 vaccine is for infants in Japan. About 1,100 babies aged 2 to 6 months will receive four doses of the vaccine. Researchers will track any side effects from the first shot until 28 days after the last shot.

This study looks at how effective the ABRYSVO® vaccine is when given to pregnant women to protect their babies from RSV, a serious respiratory virus. Researchers will review medical records of infants up to 9 months old who were hospitalized with breathing problems. The goal is t…

This study tests a new Lyme disease vaccine (VLA15) in healthy adults aged 18 to 44. Participants receive five shots over two years—four of the vaccine and one placebo—to see if different timing schedules are safe and produce a strong immune response. The goal is to find the best…

This study tests a daily pill called ritlecitinib for adults with nonsegmental vitiligo, a condition that causes white patches on the skin. About 1,571 participants will be randomly assigned to take either a low dose, a high dose, or a placebo for 52 weeks, followed by another ye…

This study tests a new oral drug, ARV-471, combined with ribociclib in people with advanced or metastatic ER+ breast cancer that no longer responds to prior treatments. About 20 adults will take both pills daily at home. Researchers will check safety and whether tumors shrink. Th…

This study tests a one-time gene therapy for adult men with moderate to severe hemophilia B, a bleeding disorder caused by a missing or faulty Factor IX gene. The therapy delivers a working copy of the gene to help the body produce its own clotting factor. Researchers will track …

This study looks at how safe and effective the drug CIBINQO is for treating atopic dermatitis (a type of eczema) in Japanese patients. Over 1,100 participants are being followed to track side effects and how well the drug clears skin. The goal is to see how the medicine works in …

This study offers continued treatment with the cancer drug palbociclib to people who have already benefited from it in earlier Pfizer studies. It includes 35 adults with breast or head/neck cancer. The main goal is to monitor safety and track any serious side effects over time.

This study tracks 29 adults in Taiwan with advanced lung cancer who have a specific gene change (EGFR-positive) and were treated with the oral drug dacomitinib. Researchers want to see how often people need to change their dose or stop treatment, and how long they live without th…

This study tracks the safety and effectiveness of Ngenla, a growth hormone injection, in children aged 3 and older with growth failure due to low growth hormone. About 565 kids in Korea will be followed for up to 6 years during routine care. The goal is to monitor side effects an…

This study tests whether adding an experimental drug (PF-06821497) to standard enzalutamide works better than standard treatments alone for men with metastatic castration-resistant prostate cancer that has progressed after abiraterone. About 600 participants will be randomly assi…

This early-stage study tests a new oral medication, PF-07985045, alone or with other cancer drugs, in people with advanced solid tumors that have a KRAS gene mutation. The cancers studied include non-small cell lung, colorectal, and pancreatic cancers. The main goals are to check…

This study tests a new medicine called vepdegestrant combined with palbociclib for people with advanced ER+/HER2- breast cancer that cannot be cured by surgery. It compares this new combo to the standard treatment of letrozole plus palbociclib. Participants take pills by mouth on…

This study tests a new drug called MK-7119 (tucatinib) combined with two standard drugs (trastuzumab and capecitabine) in 66 people with advanced HER2+ breast cancer that has stopped responding to previous treatments. The main goal is to see if the combination can shrink tumors. …

This phase 3 study compares a new oral drug, ARV-471, to the standard treatment fulvestrant in about 624 adults with advanced ER+/HER2- breast cancer that worsened after prior hormone therapy. The main goal is to see if ARV-471 delays cancer growth better than fulvestrant. Partic…

This study tests a new medicine called PF-07868489 in two parts. First, healthy adults receive a single dose to check safety and how the drug moves through the body. Then, people with pulmonary arterial hypertension (PAH) receive repeated doses over 24 weeks to see if it helps co…

This study tests whether adding talazoparib to standard enzalutamide treatment helps men with metastatic castration-resistant prostate cancer (mCRPC) live longer without their cancer getting worse. About 1,054 men took part. The goal is to see if the combination slows tumor growt…

This study tests a gene therapy called PF-06939926 in 114 boys with Duchenne muscular dystrophy (DMD), a severe muscle-wasting disease. Two-thirds of participants receive the gene therapy, while one-third get a placebo (with the option to switch to gene therapy after one year). T…

This study offers continued access to the drug crizotinib for people with certain cancers (NSCLC, ALCL, IMT) who are already benefiting from it in a previous Pfizer study that is ending. The main goal is to track long-term safety, not to test if the drug works. About 27 participa…

This study tests an oral drug called tofacitinib in children (ages 2 to 17) with moderate-to-severe ulcerative colitis, a chronic bowel disease. The goal is to see if the drug can reduce inflammation and help children reach remission, meaning fewer symptoms like urgent bowel move…

This study tests a new drug called PF-07104091 in people with advanced small cell lung, ovarian, or breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug can shrink tumors when used alone or with other cancer medicines…

This study reviews medical records of 35 adults with ROS1-positive non-small cell lung cancer that had stopped responding to prior treatments. All participants took lorlatinib pills at home until their cancer progressed. Researchers will measure how long the drug controlled the c…

This study monitors the safety and effectiveness of the drug ELREXFIO (elranatamab) in 150 Korean adults with multiple myeloma who have already tried at least three other treatments. Researchers will track side effects and how well the drug controls the cancer in everyday medical…

This study tests a new drug called sasanlimab (an immunotherapy) for people with early-stage bladder cancer that hasn't spread. In one part, patients with high-risk cancer receive sasanlimab plus standard BCG therapy, or BCG alone, to see if the combination better prevents the ca…

This study tests a new oral drug, vepdegestrant (ARV-471), combined with abemaciclib in people with advanced or metastatic ER+ breast cancer that has stopped responding to previous treatments. About 37 adults will take both pills at home daily to see if the combination is safe an…

This study tests whether adding two targeted drugs (encorafenib and cetuximab) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with a specific genetic type of advanced colorectal cancer (BRAF V600E-mutant, MSI-H/dMMR) that has spread. Ab…

This study compares two targeted drugs, lorlatinib and crizotinib, in people with advanced ALK-positive non-small cell lung cancer who have not had prior treatment. The main goal is to see if lorlatinib can delay cancer growth longer than crizotinib. About 296 participants will r…

This study tested whether adding enzalutamide to standard hormone therapy (leuprolide) can delay the spread of prostate cancer in men with high-risk disease that has not yet spread. Over 1,000 men whose cancer progressed after initial treatment (surgery or radiation) participated…

This study uses health records from nearly 99,000 adults in Ontario to see if the antiviral drug Paxlovid reduces the risk of severe COVID-19 outcomes like hospitalization or death. Researchers compared people who took Paxlovid with those who did not, tracking their health for up…

This study looks at the safety of the drug TALZENNA in people with a specific type of breast cancer (BRCA mutation-positive, HER2-negative) that cannot be removed by surgery or has returned after treatment. Participants must have had chemotherapy before and never taken TALZENNA. …

This study tests two doses (50 mg and 100 mg) of the medicine ritlecitinib, taken once daily, for severe alopecia areata—a condition causing significant hair loss on the scalp, face, and body. About 550 people aged 12 and older with at least 50% scalp hair loss will be randomly a…

This study looks at the safety of the drug Hympavzi in 50 people with congenital hemophilia A or B who do not have inhibitors. Researchers will track any side effects related to the drug. The goal is to see how well the drug works in everyday use.

This early-phase study tests the safety of a drug called tucatinib in about 25 Chinese patients with advanced HER2+ breast, stomach, or colorectal cancers that have stopped responding to standard treatments. The main goal is to see what side effects occur and how the drug moves t…

This study looks at the safety of BESPONSA in children under 18 with a type of blood cancer called acute lymphocytic leukemia (ALL) that has come back or not responded to treatment. Researchers will track side effects and liver problems for up to a year. About 10 children who hav…

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works well. About 362 participants will take part to find the…

This study offers continued treatment with avelumab to cancer patients who are already benefiting from it in earlier Pfizer studies. It includes safety monitoring and survival follow-up for people with advanced cancers like lung, ovarian, and bladder cancer. The goal is to keep p…

This study tests whether adding the drug talazoparib to standard hormone therapy (enzalutamide) can slow cancer growth better than hormone therapy alone in men with advanced prostate cancer that has spread and has a specific DNA repair mutation. About 600 men with this genetic ty…

This study tests two oral drugs, vepdegestrant and samuraciclib, taken daily at home by adults with advanced or metastatic ER+ breast cancer that no longer responds to standard treatments. The goal is to see if the combination is safe and can shrink tumors. Participants continue …

This study looks at the safety of the drug TALZENNA in men with a specific type of advanced prostate cancer that has a BRCA gene change and no longer responds to hormone therapy. Only one participant will be enrolled and followed for up to 12 months to track any side effects. The…

This study tests whether adding two targeted pills (encorafenib and binimetinib) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with advanced melanoma that has a specific BRAF gene change. About 257 adults with untreated, advanced or sp…

This study looks at the long-term safety and effects of Ngenla, a medicine already approved for children with growth hormone deficiency. One child will be followed from their first dose until November 2027. Researchers will monitor side effects, growth rate, and blood sugar level…

This study tests a new drug called elranatamab in people with multiple myeloma, a type of blood cancer, whose cancer has not responded to at least three other treatments. The drug works by helping the body's immune cells attack the cancer cells. The main goal is to see how many p…

This study looks at the long-term safety and effectiveness of the drug elranatamab in people with relapsed and refractory multiple myeloma, a type of blood cancer that has not responded to other treatments. The main goal is to track side effects like cytokine release syndrome (CR…

This study tests a new drug called elranatamab (given as a shot) against the standard drug lenalidomide (taken as a pill) in people with newly diagnosed multiple myeloma who have already had a stem cell transplant. The goal is to see if elranatamab can keep the cancer from coming…

This study follows 110 adults in Korea with a heart condition called ATTR-CM, where abnormal proteins build up in the heart. Participants take Vyndamax capsules as part of their normal care, and researchers track side effects and heart function over 10 years. The goal is to confi…

This study looks at the long-term safety and effectiveness of a gene therapy (PF-06838435) for people with severe hemophilia B, a bleeding disorder. It follows patients who already received the therapy and also tests a higher dose in new participants. The goal is to see if the tr…

This study follows 487 adults with alopecia areata who are starting Litfulo (ritlecitinib) for the first time. Researchers will monitor side effects and measure hair regrowth using the SALT score, aiming for a score of 20 or less (meaning 80% or more scalp coverage). The goal is …

This study offers continued treatment with lorlatinib for people with ALK-positive or ROS1-positive non-small cell lung cancer who are already benefiting from it in earlier Pfizer studies. The main goal is to monitor long-term safety and side effects. About 76 participants will t…

This study tests two oral drugs, vepdegestrant and PF-07220060, in people with advanced or metastatic ER+/HER2- breast cancer that has stopped responding to prior treatments. The goal is to see if the combination is safe and can shrink tumors. Participants take both pills at home…

This study looks at the long-term safety and effectiveness of the drug etrasimod for people with moderate to severe ulcerative colitis. Participants had already taken etrasimod or a placebo in earlier studies. The goal is to see if the drug can help control the disease over time,…

This study tests a new medicine (PF-07220060) taken with fulvestrant against other standard treatments for people with advanced or metastatic HR+/HER2- breast cancer whose disease worsened after prior CDK4/6 inhibitor therapy. About 333 adults will be randomly assigned to receive…

This study tests the long-term safety and effectiveness of a daily pill called ritlecitinib for people with non-segmental vitiligo, a condition that causes white patches on the skin. About 394 adults and teens who already completed a year of treatment will either continue their c…

This study is checking how safe ATGAM is for people with moderate to severe aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. Only one person is taking part, and they will be watched for 24 weeks to see if any side effects happen. The goal is to …

This study looks at how safe and effective XALKORI is for people with a specific kind of advanced lung cancer (ROS1-positive non-small cell lung cancer) who have not taken this drug before. Researchers will track side effects and measure how well the drug shrinks tumors. About 97…

This study tests an experimental drug called PF-06801591 that helps the immune system fight cancer. It is for people with advanced solid tumors or non-small-cell lung cancer that has not responded to other treatments. The goal is to see if the drug is safe and can control the can…

This early-stage study tests two new drug combinations for people with multiple myeloma that has come back or stopped responding to treatment. About 59 adults will receive elranatamab (a shot under the skin) plus either carfilzomib and dexamethasone or another drug called maplirp…

This study follows 250 UK adults with migraine who already use rimegepant for acute attacks. Over 12 weeks, participants complete daily surveys to report how quickly the drug provides meaningful pain relief and eases other symptoms. The goal is to understand consistency of respon…

This study tests whether a new daily pill, PF-08049820, can safely reduce itching and rash in adults with moderate to severe eczema. About 200 participants will take either the study drug or a placebo for 12 weeks, with regular checkups to track skin improvement. The goal is to s…

This study tested whether a nasal spray called zavegepant can quickly stop migraine pain. Adults with migraines would have used the spray at home when pain hit moderate or severe. The goal was pain freedom within 2 hours, compared to a placebo. The study was withdrawn before enro…

This study examines how patients with severe alopecia areata (an autoimmune disease causing hair loss) are using ritlecitinib in real-world clinics, not just in controlled trials. Researchers will look at medical records of about 300 people aged 12 and older who started the drug …

This study aims to understand if taking rimegepant during pregnancy affects the health of the baby or the pregnancy. Researchers will compare pregnancy outcomes in women with migraine who took rimegepant to those who did not. The study includes pregnant women aged 16 to 49 and tr…

This study looks at insurance and vaccine records to see how well the yearly updated COVID-19 vaccines protect adults and children. Researchers will compare people who got the vaccine to those who did not, tracking doctor visits, emergency care, and hospital stays. No one receive…

This study looks back at medical records of 50 Chinese adults with ALK-positive advanced non-small cell lung cancer who started treatment with the drug lorlatinib. The goal is to understand patient characteristics and how the drug is used in real-world settings. No new treatments…

This study reviewed medical records from French health insurance to see how doctors prescribe blood thinners (like apixaban or warfarin) to atrial fibrillation patients who also have a high risk of stomach bleeding. Researchers looked at which treatments were used and whether pat…

This study follows about 1,000 adults with confirmed COVID-19 or flu to see how their symptoms and quality of life change over six months. Participants fill out surveys about their health, daily activities, and vaccine history. No treatment is given; the goal is to better underst…

This study looks at how doctors prescribe treatments for ulcerative colitis (UC) and aims to create an updated treatment guide. Researchers will track 4,000 patients from a registry to see which treatments work best and when to switch therapies. The goal is to improve long-term o…

This study examines medical records from thousands of people with cancer who also had a blood clot (VTE). Researchers want to see which blood-thinning treatments are used, how well they work, and what the costs are. No new treatments are tested—just existing data is reviewed to l…

This study looks at how the antifungal drug itraconazole changes the way the body processes an experimental medicine called PF-07248144. Healthy adults will take PF-07248144 alone and then with itraconazole to compare drug levels and safety. The goal is to understand if itraconaz…

This study was designed to check if new combination tablets of nirmatrelvir and ritonavir work the same as the already-approved Paxlovid tablets. Healthy adults would have received single doses of different tablet forms under fasting conditions, and blood samples would have been …

This study looks at how the drug Palbociclib is actually used in everyday medical practice for people with a specific type of advanced breast cancer (HR+/HER2-). Researchers will analyze anonymous medical records to see how long patients take the drug and how it affects their nee…

This early-stage study tests the safety of a new medicine called PF-08049820, being developed for eczema (atopic dermatitis). About 71 healthy adults will receive either the drug or a placebo to see how the body processes it and if food affects absorption. The goal is to gather s…

This study is monitoring 1,100 adults aged 60 and older who received the Abrysvo RSV vaccine in Japan. Researchers are tracking side effects for 28 days after vaccination to confirm the vaccine's safety in real-world conditions. No new treatment is being tested—this is a safety f…

This study is a safety check for the Comirnaty COVID-19 vaccine in Korean adults. Researchers will track any side effects that happen within a week and up to a month after each dose. The goal is to spot any problems or questions about the vaccine's safety in real-world use.

This study looks at how a new medicine for atopic dermatitis (eczema) called PF-08049820 affects the way other drugs work in the body. It involves 16 healthy adult women who will take the new medicine along with birth control pills, a sedative, and a blood thinner. The goal is to…

This study looks at how doctors in Italy currently treat a tough type of multiple myeloma that doesn't respond to the three main drug classes. Researchers will collect information from medical records of about 250 patients to see how well treatments work in real life and what the…

This study looks at anonymous health records from California and Louisiana to see if the Pfizer-BioNTech COVID-19 vaccine helps prevent post-COVID conditions (long COVID). Researchers will also track who gets vaccinated. The study includes adults with a COVID-19 diagnosis and use…

This early-stage study tests a new medicine called PF-07999415 in healthy adults aged 18 to 65. Participants receive a single shot and stay in a clinic for 2 weeks to monitor for side effects. The goal is to see if the drug is safe and how the body processes it.

This early-stage study looks at how a new experimental medicine, PF-08049820, is processed by the body when taken alone and when taken with a common stomach acid drug called rabeprazole. About 18 healthy Chinese adults will take both combinations by mouth and provide blood sample…

This study follows about 1,400 people with a common type of advanced breast cancer (HR+/HER2-) who are receiving standard first-line treatment with palbociclib and hormone therapy. Researchers are collecting real-world data on how long the cancer stays under control and overall s…

This study is a disease registry that collects information from medical records of about 350 adults diagnosed with ATTR-CM, a condition where abnormal protein builds up in the heart. Researchers will look at patient characteristics, treatments, and outcomes as part of usual care—…

This study is tracking the safety of the BNT162b2 COVID-19 vaccine (including the bivalent version) in 12,000 people in Korea who received the vaccine as part of routine care. Researchers are collecting information on side effects that happen within a week and up to 28 days after…